Skip to content
Screener

Journey Medical Corporation DERM Q2 2026 earnings

Reported August 12, 2026 · After market close

Revenue$18.5MBeat by $151.3K
EPS-$0.01Beat by $0.01
Revenue estimate$18.4M
EPS estimate-$0.02
“We delivered solid performance in the second quarter, highlighted by 23% total net revenue growth, year over year, and continued progress toward profitability, driven by revenue growth and ongoing disciplined investment in our dermatology commercial infrastructure. Momentum behind Emrosi® remains strong, with sales of the product up significantly compared to both the prior-year period and the first quarter of this year. Prescription demand and payer coverage for Emrosi® are increasing as we establish the product as the best-in-class oral treatment for patients suffering from rosacea. With this progress and over $25 million in cash, we believe that we are well-positioned to execute on our strategy and deliver strong financial performance going forward.”
Claude Maraoui

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$21.9M
EPS estimate$0.02

Financials

Q2 2026

Income statement

See full
Revenue$18.5M+23.3%
Gross profit$12.4M+22.8%
Operating income$456.0K+116%
Net income-$312.0K+91.8%
EPS (diluted)-$0.01+93.8%

Balance sheet

See full
Cash & equivalents$25.6M+26.4%
Total debt$25.5M+1.0%
Total equity$32.1M+66.9%
Total assets$98.4M+21.2%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$212.95M+16.8%
Enterprise value$212.85M+13.6%
P/S3.1×-0.1×

Profitability

See full
Gross margin65.5%-4.0pp
Operating margin-4.4%—
Net margin-9%—

Returns & leverage

See full
Return on equity-23.8%—
Debt / equity0.8×-0.5×
Current ratio1.6×+0.3×

Segments

By product

See full
Emrosi$8.1M+189%
Qbrexza$5.1M-26.4%
Accutane$3.4M-1.1%
Foam Franchise Products Amzeeq Zilxi$941.0K—
Other Legacy$232.0K-68.4%

By segment

See full
Dermatological$18.5M+23.3%

FAQ

When did Journey Medical Corporation report Q2 2026 earnings?
Journey Medical Corporation (DERM) reported Q2 2026 earnings on August 12, 2026 after market close.
What were Journey Medical Corporation's Q2 2026 revenue and EPS?
Journey Medical Corporation reported revenue of $18.5M and eps of $-0.01 for Q2 2026.
Did Journey Medical Corporation beat estimates in Q2 2026?
Revenue beat the consensus estimate of $18.4M by $151.3K. EPS beat the consensus estimate of $-0.02 by $0.01.
How did Journey Medical Corporation's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 23.3% from $15.0M a year earlier and eps grew 93.8% from $-0.16.
Where can I find Journey Medical Corporation's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-094862) and the 10-Q periodic report (0001104659-26-094948) directly on SEC EDGAR. The filing index links above go to sec.gov.